Skip to main content

Table 1 Demographics of the two sample sets in this study

From: Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease

  CT AD P-value
ROW discovery set
 N 18 27 -
 AAD, yr 76.3 ± 7.1 84.5 ± 8.0 0.001a
 Gender, % (F : M) 27.8 : 72.2 63.0 : 37.0 0.033b
 PMI, hr 9.6 ± 9.4 13.4 ± 11.6 0.158a
 BW, g 1268 ± 127 1156 ± 120 0.003a
 RIN
  TC 7.9 ± 0.8 7.1 ± 1.2 0.006a
 Hemolysis ratio
  Serum 1.9 ± 0.6 1.7 ± 0.5 0.105a
APOE
  Genotype, % (ε3*3 : ε3*4 : ε4*4) 55.6 : 44.4 : 0.0 44.4 : 25.9 : 29.6 0.550c
  Allele, % (ε3 : ε4) 77.8 : 22.2 57.4 : 42.6 0.069c
NIG validation set
 N 22 36 -
 AAE, yr 73.7 ± 8.4 74.7 ± 7.3 0.556a
 Gender, % (F : M) 80.0 : 20.0 63.9 : 36.1 0.333b
 MMSE 29.3 ± 0.7 19.3 ± 5.4 4.8.E-08a
 Hemolysis ratio
  Serum 1.3 ± 0.2 1.3 ± 0.2 0.316a
APOE
  Genotype, % (ε3*3 : ε3*4) 85.7 : 14.3 55.6 : 44.4 0.056c
  Allele, % (ε3 : ε4) 92.9 : 7.1 77.8 : 22.2 0.090c
  1. Abbreviations: AAD age at death, AAE age at examination, AD Alzheimer’s disease, APOE apolipoprotein E, BW brain weight, CT control, F female, g grams, hr hours, M male, MMSE mini-mental state examination, PMI postmortem interval, RIN RNA integrity number, TC temporal cortex, yr years
  2. aCalculated by Mann-Whitney U-test between AD and CT
  3. bCalculated by Fisher’s exact test for gender distribution
  4. cCalculated by Fisher’s exact test for APOE ε4 allele carrier status (ε4 carrier and ε4 non-carrier)
  5. Data are presented as the mean ± standard deviation